Logotipo del repositorio
Logotipo del repositorio
 

Incidencia y mortalidad en pacientes con bacteriemia por Staphylococcus aureus en una Clínica de IV nivel de Barranquilla en el 2021-2022

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_16ec
dc.contributor.advisorCadena Bonfanti, Andrés Angello
dc.contributor.advisorIglesias Pertuz, Shirley
dc.contributor.authorAguilera Caro, Daney Sofia
dc.contributor.authorCuadro Diaz, Brenda Paola
dc.date.accessioned2023-12-15T19:15:26Z
dc.date.available2023-12-15T19:15:26Z
dc.date.issued2023
dc.description.abstractLa bacteriemia por Staphylococcus Aureus (SAB) es definida como el aislamiento del organismo a partir de 1 o más juego de frascos de hemocultivo recolectados mediante el uso de una técnica estéril estandarizada (1) y tiene una mortalidad asociada entre el 13 y el 60% (10), Nuestro objetivo es valorar la incidencia y mortalidad en una institución de cuarto nivel de la costa caribe colombiana durante el periodo 2021-2022, así como la influencia de los factores de riesgo y el patrón de resistencia en el desenlace. Se realiza por medio de un estudio analítico, de corte transversal retrospectivo, tomando la selección dentro de los cultivos tomados durante el periodo mencionado, aquellos que hayan sido obtenidos únicamente en sangre (Hemocultivos) con un resultado positivo para Staphylococcus aureus. La incidencia fue de aproximadamente 33 casos por año, siendo mas común en hombres, el aislamiento de MRSA fue mayor con un 68% de las SAB, la mortalidad total fue del 44% y la comorbilidad más comúnmente asociada fue la enfermedad renal crónica con un 55%. En la valoración del desenlace fatal se asoció la edad y el uso de antibiótico previo como los factores con más riesgo por lo que considerarse estas características clínicas para valorar la probabilidad de presentación y el pronóstico de la patología.spa
dc.description.abstractStaphylococcus aureus bacteremia (SAB) is defined as the isolation of the organism from 1 or more sets of blood culture bottles collected using a standardized sterile technique (1) and has an associated mortality between 13 and 60% (10), Our objective is to assess the incidence and mortality in a fourth-level institution on the Colombian Caribbean coast during the period 2021-2022, as well as the influence of risk factors and the resistance pattern on the outcome. It is carried out through a retrospective cross-sectional analytical study, selecting from the cultures taken during the mentioned time, those that have been obtained only in blood (Blood cultures) with a positive result for Staphylococcus aureus. The incidence was approximately 33 cases per year, being more common in men, the isolation of MRSA was higher with 68% of the SAB, the total mortality was 44% and the most associated comorbidity was chronic kidney disease with a 55%. In the assessment of the fatal outcome, age and previous antibiotic use are adjusted as the factors with the highest risk, so these clinical characteristics are considered to assess the probability of presentation and the prognosis of the pathology.eng
dc.format.mimetypepdf
dc.identifier.urihttps://hdl.handle.net/20.500.12442/13740
dc.language.isospa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacionaleng
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectBacteriemiaspa
dc.subjectStaphylococcus aureus Meticilino sensiblespa
dc.subjectStaphylococcus aureus Meticilino resistentespa
dc.subjectBacteremiaeng
dc.subjectMethicillin-sensitive Staphylococcus aureuseng
dc.subjectMethicillin- resistant Staphylococcus aureuseng
dc.titleIncidencia y mortalidad en pacientes con bacteriemia por Staphylococcus aureus en una Clínica de IV nivel de Barranquilla en el 2021-2022spa
dc.type.driverinfo:eu-repo/semantics/other
dc.type.spaOtros
dcterms.referencesCorey GR. Staphylococcus aureus Bboodstream infections: Definitions and treatment. Clin Infect Dis. 2009;48(SUPPL. 4).eng
dcterms.referencesKeynan Y, Rubinstein E. Staphylococcus aureus Bacteremia, Risk Factors, Complications, and Management. Crit Care Clin [Internet]. 2013;29(3):547– 62. Available from: http://dx.doi.org/10.1016/j.ccc.2013.03.008eng
dcterms.referencesGiulieri SG, Tong SYC, Williamson DA. Using genomics to understand meticillin-and vancomycin-resistant staphylococcus aureus infections. Microb Genomics. 2020;6(1).eng
dcterms.referencesCervera C, Almela M, Martínez-Martínez JA, Moreno A, Miró JM. Risk factors and management of Gram-positive bacteraemia. Int J Antimicrob Agents. 2009;34 Suppl 4(2009):26–30.eng
dcterms.referencesNOVICK RP, RICHMOND MH. Nature and Interactions of the Genetic Elements Governing Penicillinase. J Bacteriol. 1965;90(2):467–80.eng
dcterms.referencesButz AM, Christopher S. von Bartheld JB and SH-H. Staphylococcus aureus resistente a la meticilina : una descripción general de la investigación básica y clínica. Physiol Behav. 2017;176(12):139–48.eng
dcterms.referencesHassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment. Crit Care. 2017;21(1):211.eng
dcterms.referencesShorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare- associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med. 2006;34(10):2588–95.eng
dcterms.referencesIreland N. Infection report Key Points. 2014;8(32). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads /attachment_data/file/346324/Voluntary_reporting_S._aureus_bacteraemia_ England_Wales_Northern_Ireland_2013.pdfeng
dcterms.referencesHurley JC, Cosgrove SE, Carmeli Y. Comparison of mortality associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: An ecological analysis [6] (multiple letters). Clin Infect Dis. 2003;37(6):866–9.eng
dcterms.referencesHincapié-Osorno C, Caraballo-Cordovez C, Tibaduiza-García MF, Garcés- Rodríguez D de J, Echeverri-Toro L, Ascuntar-Tello J, et al. Caracterización clínica y microbiológica de la bacteriemia por Staphylococcus aureus. Acta Médica Colomb. 2018;43(4):200–6.spa
dcterms.referencesNader N, Medina RI, Pescador LÁ, Mantilla BM, Bravo JS, Gómez CH. Caracterización de los pacientes con bacteriemia por Staphylococcus aureus resistente a la meticilina en un hospital militar de alta complejidad. Biomédica. 2019;39:86–95.spa
dcterms.referencesCastillo JS, Leal AL, Cortes JA, Alvarez CA, Sanchez R, Buitrago G, et al. Mortality among critically ill patients with bacteremia : a multicenter cohort study in Colombia Study setting. 2012;32(1):343–50.eng
dcterms.referencesNaves KSC, Trindade NV da, Gontijo Filho PP. Methicillin-resistant Staphylococcus aureus bloodstream infection: risk factors and clinical outcome in non-intensive-care units. Rev Soc Bras Med Trop. 2012;45(2):189–93.eng
dcterms.referencesMaestre Zabala SS del C, Henao Cabarcas LC. Caracterización de infecciones en adultos por staphylococcus aureus meticilino-resistente (SAMR) en una institución de salud de IV nivel, Barranquilla 2016. Biociencias. 2017;12(2):71–92.spa
dcterms.referencesShinefield HR, Ruff NL. Staphylococcal Infections: A Historical Perspective. Infect Dis Clin North Am. 2009;23(1):1–15.eng
dcterms.referencesTong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61.eng
dcterms.referencesS.I. B, K.H. V, E.A. H, F.A. C. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin- resistant Staphylococcus aureus. Arch Intern Med [Internet]. 2002;162(19):2229–35. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed5&NEWS=N&AN=2002383391eng
dcterms.referencesQue Y, Moreillon P. 196 - Staphylococcus aureus (incluido el síndrome del shock tóxico) [Internet]. Nineth Edi. Mandell, Douglas y Bennet Enfermedades Infecciosas. Principios y Práctica. Elsevier Espa8#241;a, S.L.U.; 2016. 2356–2392 p. Available from: http://dx.doi.org/10.1016/B978- 84-9022-917-0/00196-7eng
dcterms.referencesZendejas G, Avalos H, Soto M. Microbiologia general de Staphylococcus aeurus: Generalidades de patogenecidad, metodos de identificacion. Rev Biomed. 2014;25(3):129–43.eng
dcterms.referencesTaylor TA, Unakal CG. Staphylococcus aureus. Food Microbiol Fundam Front Third Ed. 2014;493–518.eng
dcterms.referencesBou G, Fernández-Olmos A, García C, Sáez-Nieto JA, Valdezate S. Métodos de identificación bacteriana en el laboratorio de microbiología. Vol. 29, Enfermedades Infecciosas y Microbiologia Clinica. 2011. 601–608 p.spa
dcterms.referencesPasachova J, Ramirez S, Muñoz L. Staphylococcus aureus: generalidades, mecanismos de patogenicidad y colonización celular. Nova [Internet]. 2019;17(32):25–38. Available from: http://www.scielo.org.co/pdf/nova/v17n32/1794-2470-nova-17-32-25.pdfspa
dcterms.referencesMurray P, Roshental K, Pfaller M. Staphylococcus y otros cocos grampositivos relacionados. Microbiología Médica. Elsevier-Mosby. 2013. 7: 174-176.spa
dcterms.referencesGram C, Aspectos P, Seija V. COCOS GRAM POSITIVOS: Aspectos prácticos. :1–5.spa
dcterms.referencesSilhavy TJ, Kahne D, Walker S. The Bacterial Cell Envelope1 T. J. Silhavy, D. Kahne and S. Walker, . Cold Spring Harb Perspect Biol [Internet]. 2010;2:1–16. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857177/pdf/cshperspect- PRK-a000414.pdfeng
dcterms.referencesJawetz, Melnick & AM. Microbiologia Medica. Vol. 53, Journal of Chemical Information and Modeling. 2016. 866 p.eng
dcterms.referencesMurray P, Roshental K, Pfaller M. Staphylococcus y otros cocos grampositivos relacionados. Microbiol Médica Elsevier-Mosby. 2013;7: 174- 176.eng
dcterms.referencesAllison a. C. Protein and Sugar Export and Assembly Ain Gram-Positive Bacteria. Vol. 28, Immunology. 1975. 1180–1181 p.eng
dcterms.referencesSilhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harb Perspect Biol. 2010;2(5).eng
dcterms.referencesia Gutiérrez-Venegas G. Ácido Lipoteicoico: Receptores Y Mecanismo De Transducción*. Rev Educ Bioquímica. 2006;25(2):41–9.spa
dcterms.referencesBrown S, Santa Maria JP, Walker S. Wall teichoic acids of gram-positive bacteria. Annu Rev Microbiol. 2013;67(6):313–36.eng
dcterms.referencesFoster TJ. Surface proteins of staphylococcus aureus. Gram-Positive Pathog. 2019;599–617.eng
dcterms.referencesFoster TJ. The MSCRAMM Family of Cell-Wall-Anchored Surface Proteins of Gram-Positive Cocci. Trends Microbiol [Internet]. 2019;27(11):927–41. Available from: https://doi.org/10.1016/j.tim.2019.06.007eng
dcterms.referencesClarke SR, Foster SJ. Surface Adhesins of Staphylococcus aureus. Vol. 51, Advances in Microbial Physiology. 2006. 187–224 p.eng
dcterms.referencesFoster TJ, Geoghegan JA, Ganesh VK, Höök M. Adhesion, invasion and evasion: The many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol [Internet]. 2014;12(1):49–62. Available from: http://dx.doi.org/10.1038/nrmicro3161eng
dcterms.referencesCheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence [Internet]. 2021;12(1):547–69. Available from: https://doi.org/10.1080/21505594.2021.1878688eng
dcterms.referencesGanesh VK, Rivera JJ, Smeds E, Ko YP, Bowden MG, Wann ER, et al. A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. PLoS Pathog. 2008;4(11).eng
dcterms.referencesDeivanayagam CCS, Wann ER, Chen W, Carson M, Rajashankar KR, Höök M, et al. A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: Crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. EMBO J. 2002;21(24):6660–72.eng
dcterms.referencesXiang H, Feng Y, Wang J, Liu B, Chen Y, Liu L, et al. Crystal structures reveal the multi-ligand binding mechanism of Staphylococcus aureus ClfB. PLoS Pathog. 2012;8(6).eng
dcterms.referencesCorrigan RM, Miajlovic H, Foster TJ. Surface proteins that promote adherence of Staphylococcus aureus to human desquamated nasal epithelial cells. BMC Microbiol. 2009;9:1–10.eng
dcterms.referencesBurke FM, Di Poto A, Speziale P, Foster TJ. The A domain of fibronectin- binding protein B of Staphylococcus aureus contains a novel fibronectin binding site. FEBS J. 2011;278(13):2359–71.eng
dcterms.referencesPeacock SJ, Foster TJ, Cameron BJ, Berendt AR. Bacterial fibronectin- binding proteins and endothelial cell surface fibronectin mediate adherence of Staphylococcus aureus to resting human endothelial cells. Microbiology. 1999;145(12):3477–86.eng
dcterms.referencesOliveira D, Borges A, Simões M. Staphylococcus aureus toxins and their molecular activity in infectious diseases. Toxins (Basel). 2018;10(6).eng
dcterms.referencesKayan Tam and Victor J. Torres. Staphylococcus aureus Secreted Toxins & Extracellular Enzymes. Physiol Behav [Internet]. 2017;176(10):139–48. Available from: file:///C:/Users/Carla%0ACarolina/Desktop/Artigos%0Apara%0Aacrescentar %0Ana%0Aqualificação/The%0Aimpact%0Aof%0Abirth%0Aweight%0Aon% 0Acardiovascular%0Adisease%0Arisk%0Aineng
dcterms.referencesKong C, Neoh HM, Nathan S. Targeting Staphylococcus aureus toxins: A potential form of anti-virulence therapy. Toxins (Basel). 2016;8(3):1–21.eng
dcterms.referencesBukowski M, Wladyka B, Dubin G. Exfoliative toxins of Staphylococcus aureus. Toxins (Basel). 2010;2(5):1148–65.eng
dcterms.referencesLadhani S. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Immunol Med Microbiol. 2003;39(2):181–9.eng
dcterms.referencesGrumann D, Nübel U, Bröker BM. Staphylococcus aureus toxins - Their functions and genetics. Infect Genet Evol [Internet]. 2014;21:583–92. Available from: http://dx.doi.org/10.1016/j.meegid.2013.03.013eng
dcterms.referencesLina G, Bohach GA, Nair SP, Hiramatsu K, Jouvin-Marche E, Mariuzza R. Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis. 2004;189(12):2334–6.eng
dcterms.referencesFleischer B, Schrezenmeier H. T cell stimulation by staphylococcal enterotoxins: Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med. 1988;167(5):1697–707.eng
dcterms.referencesBalasubramanian D, Harper L, Shopsin B, Torres VJ. Staphylococcus aureus pathogenesis in diverse host environments. Pathog Dis. 2017;75(1):1–13.eng
dcterms.referencesJenul C, Horswill AR. Regulation of staphylococcus aureus virulence. Gram- Positive Pathog. 2019;669–86.eng
dcterms.referencesVillanueva M, García B, Valle J, Rapún B, Ruiz De Los Mozos I, Solano C, et al. Sensory deprivation in Staphylococcus aureus. Nat Commun [Internet]. 2018;9(1):1–12. Available from: http://dx.doi.org/10.1038/s41467-018-02949- yeng
dcterms.referencesHeyer G, Saba S, Adamo R, Rush W, Soong G, Cheung A, et al. Staphylococcus aureus agr and sarA functions are required for invasive infection but not inflammatory responses in the lung. Infect Immun. 2002;70(1):127–33.eng
dcterms.referencesAntibioticos FGDELOS. Farmacología general de los antibióticos. 1941;1– 27.spa
dcterms.referencesLynn P. Principios de la prescripción antibiótica en la unidad de cuidados intensivos y en pacientes con lesión renal aguda [Internet]. Third Edit. Cuidados intensivos en nefrología. Elsevier Espa8#241;a, S.L.U.; 2019. 567–573 p. Available from: https://www-clinicalkey- es.pbidi.unam.mx:2443/#!/browse/book/3-s2.0-C20190006851spa
dcterms.referencesBRUNTON, CHABNER K. LAS BASES FARMACOLOGICAS DE LA TERAPPEUTICA. 2546.spa
dcterms.referencesOpal SM. 18 - Mecanismos moleculares de resistencia antimicrobiana en las bacterias [Internet]. Nineth Edi. Mandell, Douglas y Bennett. Enfermedades infecciosas. Principios y práctica. Elsevier Espa8#241;a, S.L.U.; 2021. 222– 239 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-499-2/00018- 7spa
dcterms.referencesLozano C, Torres C. Actualización en la resistencia antibiótica en Gram positivos. Enferm Infecc Microbiol Clin [Internet]. 2017;35(Supl 1):2–8. Available from: http://dx.doi.org/10.1016/S0213-005X(17)30028-9spa
dcterms.referencesLakhundi S, Zhang K. Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin Microbiol Rev. 2018;31(4):1–103.eng
dcterms.referencesGiraldo-Hoyos N. History of penicillin: Beyond heroes, a social construction. Iatreia. 2021;34(2):172–9.spa
dcterms.referencesW. M. M. K. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science (80- ). 1944;99(2579):452–3.eng
dcterms.referencesJevons MP. “Celbenin” -resistant Staphylococci. Br Med J. 1961;1(5219):124–5.eng
dcterms.referencesRincón S, Panesso D, Díaz L, Carvajal LP, Reyes J, Munita JM, et al. Resistencia a antibióticos de última línea en cocos gram positivos: La era posterior a la vancomicina. Biomedica. 2014;34(SUPPL.1):191–208.spa
dcterms.referencesPeterson LR. Bad Bugs, No Drugs: No ESCAPE Revisited. Clin Infect Dis. 2009;49(6):991–2.eng
dcterms.referencesVestergaard M, Frees D, Ingmer H. Antibiotic resistance and the MRSA problem. Gram-Positive Pathog. 2019;747–65.eng
dcterms.referencesForbes GB. Penicillin-resistant Staphylococci. Br Med J. 1949;1(4604):591– 2.eng
dcterms.referencesOlsen JE, Christensen H, Aarestrup FM. Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci. J Antimicrob Chemother. 2006;57(3):450–60.eng
dcterms.referencesFirth N, Jensen SO, Kwong SM, Skurray RA, Ramsay JP. Staphylococcal Plasmids, Transposable and Integrative Elements. Microbiol Spectr. 2018;6(6).eng
dcterms.referencesItou T, Katayama Y, Hiramatsu K. A new mobile genetic element, staphylococcal cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Nippon saikingaku zasshi Japanese J Bacteriol. 2000;55(3):483–98.eng
dcterms.referencesPatiño NM. Penicilina. 1940;(cuadro 1).eng
dcterms.referencesVignoli R, Seija V. Principales mecanismos de resistencia antibiótica. Book [Internet]. 2000;649–62. Available from: http://www.higiene.edu.uy/cefa/cefaed2006.htmspa
dcterms.referencesTipper DJ, Strominger JL. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci U S A. 1965;54(4):1133–41.eng
dcterms.referencesMalouin F, Bryan LE. Modification of penicillin-binding proteins as mechanisms of β-lactam resistance. Antimicrob Agents Chemother. 1986;30(1):1–5.eng
dcterms.referencesHartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with β-lactam resistance in Staphylococcus aureus. J Bacteriol. 1984;158(2):513– 6.eng
dcterms.referencesUtsui Y, Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1985;28(3):397–403.eng
dcterms.referencesOlarte-Luis T, Cáceres-Galíndez D, Cortés JA. Nuevas cefalosporinas. Rev Chil infectología. 2018;35(5):465–75.eng
dcterms.referencesLee AS, De Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Prim [Internet]. 2018;4(May):1–23. Available from: http://dx.doi.org/10.1038/nrdp.2018.33eng
dcterms.referencesLogan LK, Blumer JL, Toltzis P. 234 - Antibiotic Resistance [Internet]. Eighth Edi. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases. Elsevier Inc.; 2022. 2320-2339.e10 p. Available from: https://doi.org/10.1016/B978-0- 323-37692-1.00234-3eng
dcterms.referencesIto T, Hiramatsu K, Oliveira DC, De Lencastre H, Zhang K, Westh H, et al. Classification of staphylococcal cassette chromosome mec (SCCmec): Guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother. 2009;53(12):4961–7.eng
dcterms.referencesOliveira DC, Tomasz A, De Lencastre H. Secrets of success of a human pathogen: Molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus. Lancet Infect Dis. 2002;2(3):180–9.eng
dcterms.referencesAgnieszka Misiura, Ying Z. Pigli, Susan Boyle-Vavra†, Robert S. Daum†, Martin R. Boocock‡ and PAR. Roles of two large serine recombinases in mobilizing the methicillin-resistance cassette SCCmec. Bone. 2013;23(1):1– 7.eng
dcterms.referencesChirag M Lakhani1, Braden T Tierney1, 2, Arjun K Manrai1, 3, Jian Yang4, 5, Peter M Visscher#4, 5,*, and Chirag J Patel#1 1Department, Kuschner. Staphylococcal SCCmec elements encode an active MCM–like helicase and thus may be replicative. Physiol Behav. 2017;176(3):139–48.eng
dcterms.referencesShajari G, Khorshidi A, Moosavi G. Vancomycin resistance in Staphylococcus aureus strains. Arch Razi Inst. 2017;90(54):107–10.eng
dcterms.referencesLund LC, Holzknecht BJ, Justesen US. vancomycin-resistant enterococcal infections. Ugeskr Laeger. 2018;180(16).eng
dcterms.referencesManquat,g; Croize JSJ. Failure of teicolpanin treatment associated with increase in MIC during therapur of S Aureus septicemia. 1991;(1979):731–2.eng
dcterms.referencesGardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest. 2014;124(7):2836–40.eng
dcterms.referencesArthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol. 1993;175(1):117–27.eng
dcterms.referencesHandwerger S, Skoble J. Identification of chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1995;39(11):2446–53.eng
dcterms.referencesPérichon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(11):4580–7.eng
dcterms.referencesReynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989;8(11):943–50.eng
dcterms.referencesArthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993;37(8):1563–71.eng
dcterms.referencesVon Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis. 2002;2(11):677–85.eng
dcterms.referencesLaupland KB, Lyytikäinen O, Søgaard M, Kennedy KJ, Knudsen JD, Ostergaard C, et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: A multinational population-based surveillance study. Clin Microbiol Infect. 2013;19(5):465–71.eng
dcterms.referencesMcMullan BJ, Campbell AJ, Blyth CC, Chase McNeil J, Montgomery CP, Tong SYC, et al. Clinical management of staphylococcus aureus bacteremia in neonates, children, and adolescents. Pediatrics. 2020;146(3).eng
dcterms.referencesVanderkooi OG, Gregson DB, Kellner JD, Laupland KB. Staphylococcus aureus bloodstream infections in children: A population-based assessment. Paediatr Child Health (Oxford). 2011;16(5):276–80.eng
dcterms.referencesAsgeirsson H, Gudlaugsson O, Kristinsson KG, Heiddal S, Kristjansson M. Staphylococcus aureus bacteraemia in Iceland, 1995-2008: Changing incidence and mortality. Clin Microbiol Infect [Internet]. 2011;17(4):513–8. Available from: http://dx.doi.org/10.1111/j.1469-0691.2010.03265.xeng
dcterms.referencesLarsen M V., Harboe ZB, Ladelund S, Skov R, Gerstoft J, Pedersen C, et al. Major but differential decline in the incidence of Staphylococcus aureus bacteraemia in HIV-infected individuals from 1995 to 2007: A nationwide cohort study. HIV Med. 2012;13(1):45–53.eng
dcterms.referencesMathews WC, Caperna JC, Barber RE, Torriani FJ, Miller LG, May S, et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr. 2005;40(2):155–60.eng
dcterms.referencesGoodman RP, Squier C, Arbeit RD, Singh N, Wagener MM, Yu VL. Nasal Carriage of and Infection with. Ann Intern Med. 1999;130(3):221–5.eng
dcterms.referencesJacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and aids-related complex. Am J Med.1988;85(2):172–6.eng
dcterms.referencesKim YS, Kim J, Cheon S, Sohn KM. Higher risk for all-cause mortality of staphylococcus aureus bacteremia in patients with non-dialysis dependent chronic kidney disease. Infect Chemother. 2020;52(1):82–92.eng
dcterms.referencesPrezant DJ. Effect of uremia and its treatment on pulmonary function. Lung. 1990;168(1):1–14.eng
dcterms.referencesTaylor GD, Gravel D, Johnston L, Embil J, Holton D, Paton S. Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am J Infect Control. 2004;32(3):155–60.eng
dcterms.referencesChaudry MS, Gislason GH, Kamper AL, Rix M, Larsen AR, Petersen A, et al. Increased risk of Staphylococcus aureus bacteremia in hemodialysis—A nationwide study. Hemodial Int. 2019;23(2):230–8.eng
dcterms.referencesLata C, Girard L, Parkins M, James MT. Catheter-related bloodstream infection in end-stage kidney disease: A Canadian narrative review. Can J Kidney Heal Dis [Internet]. 2016;3(1):1–12. Available from: http://dx.doi.org/10.1186/s40697-016-0115-8eng
dcterms.referencesEngemann JJ, Friedman JY, Reed SD, Robert I, Szczech LA, Kaye KS, et al. C LINICAL O UTCOMES AND C OSTS D UE TO S TAPHYLOCOCCUS AUREUS B ACTEREMIA A MONG P ATIENTS R ECEIVING L ONG -T ERM H EMODIALYSIS. 2013;eng
dcterms.referencesDantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173(21):1970–9.eng
dcterms.referencesSchecter W. Catheter-related bloodstream infections. Surg Infect (Larchmt). 2013;115–115.eng
dcterms.referencesMermel LA. Defining intravascular catheter-related infections: A plea for uniformity. Nutrition. 1997;13(4 SUPPL. 1):2S-4S.eng
dcterms.referencesMermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection. ClinInfectDis. 2014;49(1):1–45.eng
dcterms.referencesFortún J. Infections related to intravascular devices used for infusion therapy. Enferm Infecc Microbiol Clin [Internet]. 2008;26(3):168–74. Available from: http://dx.doi.org/10.1157/13116754eng
dcterms.referencesSteinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: Impact of intravascular devices and methicillin resistance. Clin Infect Dis. 1996;23(2):255–61.eng
dcterms.referencesPark KH, Lee YM, Hong HL, Kim T, Park HJ, Park SY, et al. Persistent Catheter-Related Staphylococcus aureus Bacteremia after Catheter Removal and Initiation of Antimicrobial Therapy. PLoS One. 2012;7(10).eng
dcterms.referencesNora B. Respuesta Inmunitaria. Fac Med UNNE [Internet]. 2007;1–19. Available from: https://med.unne.edu.ar/sitio/multimedia/imagenes/ckfinder/files/files/Carrera -Medicina/BIOQUIMICA/inmunitaria.pdfeng
dcterms.referencesKatzung BG, Masters SB, Trevor AJ. Farmacologia Básica y clínica. Capitulo 36: farmacos aintiinflamatorios no esteroideos,antirreumaticos, modificadores de la enfermedad, analgesicos no opides y analgesicos usados en gota.spa
dcterms.referencesAltschul DM, Deary IJ, Data I, Mental K. Impact of immunosuppressive agents on clinical manifestations and outcome of Staphylococcus aureus bloodstream infection – A propensity score matched analysis in two large, prospectively evaluated cohorts. 2019;1–31.eng
dcterms.referencesAkash MSH, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes- associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol [Internet]. 2020;202(5):953–65. Available from: https://doi.org/10.1007/s00203-020-01818-xeng
dcterms.referencesCasqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012;16(7):27.eng
dcterms.referencesCasqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012;16(7):27.eng
dcterms.referencesSilva V, Almeida L, Gaio V, Cerca N, Manageiro V, Caniça M, et al. Biofilm formation of multidrug-resistant mrsa strains isolated from different types of human infections. Pathogens. 2021;10(8).eng
dcterms.referencesGupta S, Koirala J, Khardori R, Khardori N. Infections in Diabetes Mellitus and Hyperglycemia. Infect Dis Clin North Am. 2007;21(3):617–38.eng
dcterms.referencesNabera CK. Staphylococcus aureus bacteremia: Epidemiology, pathophysiology, and management strategies. Clin Infect Dis. 2009;48(SUPPL. 4):231–7.eng
dcterms.referencesMcDevitt D, Francois P, Vaudaux P, Foster TJ. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol. 1994;11(2):237–48.eng
dcterms.referencesMassey RC, Kantzanou MN, Fowler T, Day NPJ, Schofield K, Wann ER, et al. Fibronectin-binding protein A of Staphylococcus aureus has multiple, substituting, binding regions that mediate adherence to fibronectin and invasion of endothelial cells. Cell Microbiol. 2001;3(12):839–51.eng
dcterms.referencesMassey RC, Dissanayeke SR, Cameron B, Ferguson D, Foster TJ, Peacock SJ. Functional blocking of Staphylococcus aureus adhesins following growth in ex vivo media. Infect Immun. 2002;70(10):5339–45.eng
dcterms.referencesKroh HK, Panizzi P, Bock PE. Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. Proc Natl Acad Sci U S A. 2009;106(19):7786–91.eng
dcterms.referencesKawabata SI, Iwanaga S. Structure and function of staphylothrombin. Semin Thromb Hemost. 1994;20(4):345–50.eng
dcterms.referencesPeetermans M, Vanassche T, Liesenborghs L, Claes J, Velde G Vande, Kwiecinksi J, et al. Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections. BMC Microbiol. 2014;14(1):1–12.eng
dcterms.referencesAl. U et. Pathogenesis of Staphylococcus aureus Bloodstream Infections HHS Public Access. Physiol Behav. 2016;176(1):139–48.eng
dcterms.referencesRooijakkers SHM, Ruyken M, van Roon J, van Kessel KPM, van Strijp JAG, van Wamel WJB. Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell Microbiol. 2006;8(8):1282– 93.eng
dcterms.referencesWright AJ, Higginbottom A, Philippe D, Upadhyay A, Bagby S, Read RC, et al. Characterisation of receptor binding by the chemotaxis inhibitory protein of Staphylococcus aureus and the effects of the host immune response. Mol Immunol. 2007;44(10):2507–17.eng
dcterms.referencesChavakis T, Hussain M, Kanse SM, Peters G, Bretzel RG, Flock JI, et al. Staphylococcus aureus extracellular adherence protein serves as anti- inflammatory factor by inhibiting the recruitment of host leukocytes. Nat Med. 2002;8(7):687–93.eng
dcterms.referencesKim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol. 2012;15(1):92–9.eng
dcterms.referencesAtkins KL, Burman JD, Chamberlain ES, Cooper JE, Poutrel B, Bagby S, et al. S. aureus IgG-binding proteins SpA and Sbi: Host specificity and mechanisms of immune complex formation. Mol Immunol. 2008;45(6):1600– 11.eng
dcterms.referencesBeavers WN, Skaar EP. Neutrophil-generated oxidative stress and protein damage in Staphylococcus aureus. Pathog Dis. 2016;74(6):1–15.eng
dcterms.referencesDe Jong NWM, Ramyar KX, Guerra FE, Nijland R, Fevre C, Voyich JM, et al. Immune evasion by a staphylococcal inhibitor of myeloperoxidase. Proc Natl Acad Sci U S A. 2017;114(35):9439–44.eng
dcterms.referencesBayer AS, Cheng D, Yeaman MR, Corey GR, McClelland RS, Harrel LJ, et al. In vitro resistance to thrombin-induced platelet microbicidal protein among clinical bacteremic isolates of Staphylococcus aureus correlates with an endovascular infectious source. Antimicrob Agents Chemother. 1998;42(12):3169–72.eng
dcterms.referencesSass P, Bierbaum G. Native graS mutation supports the susceptibility of Staphylococcus aureus strain SG511 to antimicrobial peptides. Int J Med Microbiol [Internet]. 2009;299(5):313–22. Available from: http://dx.doi.org/10.1016/j.ijmm.2008.10.005eng
dcterms.referencesDinges MM, Orwin PM, Schlievert PM, Biology S, The OF. Exotoxins of. Society. 2000;13(1):16–34.eng
dcterms.referencesJung N, Rieg S. Essentials in the management of S. aureus bloodstream infection. Infection [Internet]. 2018;46(4):441–2. Available from: https://doi.org/10.1007/s15010-018-1130-8eng
dcterms.referencesFowler VG, Olsen MK, Corey GR, Cheng AC, Dudley T, Oddone EZ. Clinical Identifiers of Complicated S. aureus bacteremia. Arch Intern Med. 2003;163(17):2066–72.eng
dcterms.referencesHoerr V, Franz M, Pletz MW, Diab M, Niemann S, Faber C, et al. S. aureus endocarditis: Clinical aspects and experimental approaches. Int J Med Microbiol [Internet]. 2018;308(6):640–52. Available from: http://dx.doi.org/10.1016/j.ijmm.2018.02.004eng
dcterms.referencesBaddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Vol. 132, Circulation. 2015. 1435–1486 p.eng
dcterms.referencesBaddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Vol. 132, Circulation. 2015. 1435–1486 p.eng
dcterms.referencesBaddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Vol. 132, Circulation. 2015. 1435–1486 p.eng
dcterms.referencesBaddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Vol. 132, Circulation. 2015. 1435–1486 p.eng
dcterms.referencesThuny F, Disalvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, et al. Risk of embolism and death in infective endocarditis: Prognostic value of echocardiography - A prospective multicenter study. Circulation. 2005;112(1):69–75.eng
dcterms.referencesChang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicenter study of staphylococcus aureus bacteremia: Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore). 2003;82(5):322–32.eng
dcterms.referencesDzupova O, Rozsypal H, Prochazka B, Benes J. Acute bacterial meningitis in adults: Predictors of outcome. Scand J Infect Dis. 2009;41(5):348–54.eng
dcterms.referencesAguilar J, Urday-Cornejo V, Donabedian S, Perri M, Tibbetts R, Zervos M. Staphylococcus aureus meningitis case series and literature review. Medicine (Baltimore). 2010;89(2):117–25.eng
dcterms.referencesHorino T, Hori S. Metastatic infection during Staphylococcus aureus bacteremia. J Infect Chemother [Internet]. 2020;26(2):162–9. Available from: https://doi.org/10.1016/j.jiac.2019.10.003eng
dcterms.referencesPintado V, Meseguer MA, Fortún J, Cobo J, Navas E, Quereda C, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis. 2002;21(12):864–8.eng
dcterms.referencesGrewal S, Hocking G, Wildsmith JAW. Epidural abscesses. Br J Anaesth. 2006;96(3):292–302.eng
dcterms.referencesGrewal S, Hocking G, Wildsmith JAW. Epidural abscesses. Br J Anaesth. 2006;96(3):292–302.eng
dcterms.referencesLiu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis. 2011;52(3):285–92.eng
dcterms.referencesSelf WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis. 2016;63(3):300–9.eng
dcterms.referencesTsai YF, Ku YH. Necrotizing pneumonia: A rare complication of pneumonia requiring special consideration. Curr Opin Pulm Med. 2012;18(3):12–4.eng
dcterms.referencesBandaru S, Manthri S, Sundareshan V, Prakash V. Empyema Necessitans in the Setting of Methicillin-Susceptible Staphylococcus aureus Causing Pneumonia and Bacteremia . Case Rep Infect Dis. 2018;2018:1–5.eng
dcterms.referencesGillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing panton-valentine leukocidin. Clin Infect Dis. 2007;45(3):315–21.eng
dcterms.referencesLew PDP, Waldvogel PFA. Osteomyelitis. Lancet. 2004;364(9431):369–79.eng
dcterms.referencesSia IG, Berbari EF. Osteomyelitis. Best Pract Res Clin Rheumatol. 2006;20(6):1065–81.eng
dcterms.referencesKremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Joseph Melton L, Huddleston PM. Trends in the epidemiology of osteomyelitis a population- based study, 1969 to 2009. J Bone Jt Surg - Am Vol. 2014;97(10):837–45.eng
dcterms.referencesHendrick JW. Diagnosis and management of osteomyelitis. J Am Med Assoc. 1957;164(2):127–33.eng
dcterms.referencesRachman T. Osteomyelitis. Angew Chemie Int Ed 6(11), 951–952. 2018;10– 27.eng
dcterms.referencesChong YP, Moon SM, Bang KM, Park HJ, Park SY, Kim MN, et al. Treatment duration for uncomplicated staphylococcus aureus bacteremia to prevent relapse: Analysis of a prospective observational cohort study. Antimicrob Agents Chemother. 2013;57(3):1150–6.eng
dcterms.referencesJernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: A meta-analysis. Ann Intern Med. 1993;119(4):304–11.eng
dcterms.referencesCalain P, Vaudaux P, Auckenthaler R, Lew D, Waldvogel F, Hirschel B. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987;155(2):187–91.eng
dcterms.referencesSmall PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990;34(6):1227–31.eng
dcterms.referencesKarchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al. Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus. N Engl J Med. 2006;653–65.eng
dcterms.referencesMarkowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117(5):390–8.eng
dcterms.referencesRaad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374–80.eng
dcterms.referencesShorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56(5):923–9.eng
dcterms.referencesRehm SJ, Tice A. Staphylococcus aureus: Methicillin-susceptible S. aureus to methicillin-resistant S. aureus and vancomycin-resistant S. aureus. Clin Infect Dis. 2010;51(SUPPL. 2).eng
dcterms.referencesRonat JB, Oueslati S, Natale A, Kesteman T, Elamin W, Langendorf C, et al. Validation of Three MicroScan® Antimicrobial Susceptibility Testing Plates Designed for Low-Resource Settings. Diagnostics. 2022;12(9):1–17.eng
dcterms.referencesFramer J. Manual of Clinical Microbiology 8th edition. Man Clin Microbiol. 1995;(January):438–42.eng
dcterms.referencesFramer J. Manual of Clinical Microbiology 8th edition. Man Clin Microbiol. 1995;(January):438–42.eng
oaire.versioninfo:eu-repo/semantics/acceptedVersion
sb.programaEspecialización en Medicina Internaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
810.04 KB
Formato:
Adobe Portable Document Format
Descargar
Miniatura
Nombre:
PDF_Resumen.pdf
Tamaño:
238.99 KB
Formato:
Adobe Portable Document Format
Descargar

Colecciones

Especialización

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca